Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

A new study designs drugs that bind to intrinsically disordered proteins that are extremely difficult to target due to their flexible nature.

Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy The 2022 AUA/ASTRO guidelines recommend 18-36 months of androgen deprivation therapy (ADT) ...

A summary of the existing avengers in the treatment of metastatic castration-resistant prostate cancer is provided. The goal is to provide a framework to optimize sequencing of existing avengers to ...

Researchers have unveiled important new insights into how hormones known as androgens act on our cells - and the discovery could boost efforts to develop better treatments for prostate, ovarian and ...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...

The choice of menopausal hormone therapy (MHT) is traditionally guided by the need to alleviate climacteric symptoms by ...

Researchers have created an epigenetic tool which has implications for medicine, sports, and agriculture. Researchers from the University of Otago -- Ōtākou Whakaihu Waka have created a world-first ...